In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 75 of 294

Sort by

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]	Technology appraisal guidance	3 September 2026
Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]	Technology appraisal guidance	TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]	Technology appraisal guidance	TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]	Technology appraisal guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]	Technology appraisal guidance	TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]	Technology appraisal guidance	13 May 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]	Technology appraisal guidance	13 May 2026
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults [ID1297]	Technology appraisal guidance	28 July 2021
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]	Technology appraisal guidance	TBC
DCVax-L for treating glioblastoma [ID836]	Technology appraisal guidance	TBC
Decitabine–cedazuridine with venetoclax for untreated acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]	Technology appraisal guidance	24 March 2027
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]	Technology appraisal guidance	TBC
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]	Technology appraisal guidance	24 February 2027
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]	Technology appraisal guidance	TBC
Deuruxolitinib for treating severe alopecia areata [ID6597]	Technology appraisal guidance	8 October 2026
Deutetrabenazine for treating tardive dyskinesia [ID6550]	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TSID10725]	Technology appraisal guidance	TBC
Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]	Technology appraisal guidance	TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]	Technology appraisal guidance	TBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]	Technology appraisal guidance	TBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]	Technology appraisal guidance	18 June 2026
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]	Technology appraisal guidance	23 July 2026
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance	TBC

Results per page

10
25
50
All